Lixiana Waging Hand-to-Hand Combat with Xarelto in DOAC Market: Encise FY2018 Snapshot

Daiichi Sankyo’s direct oral anticoagulants (DOAC) Lixiana (edoxaban) enjoyed bullish growth in Japan in the year ended March 2019, aggressively closing in on the market leader Xarelto (rivaroxaban), according to Encise’s FY2018 snapshot report released on April 5. On an...read more